文献速递胸部肿瘤放疗消化道肿瘤放疗

局部晚期非小细胞肺癌患者接受同期大分割放化疗与三周铂类双药化疗后食管毒性过高

Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-07-07

该回顾性观察研究纳入2012至2017年41例III期非小细胞肺癌患者(<70岁,WHO体能评分0-1),接受同期铂类双药化疗与66 Gy/24次放疗。中位随访4.7年,5例死亡(4例食管穿孔或瘘,1例肺出血),≥3级食管毒性16例,晚期≥3级食管毒性5例(12%),中位总生存19个月。作者结论为毒性出乎意料地高。

要点

  • 41例III期NSCLC患者接受66 Gy/24次同期铂类双药化疗,≥3级食管毒性16例。
  • 5例发生晚期≥3级食管毒性(12%),5例死亡中4例死于食管穿孔或瘘。
  • 中位随访4.7年,中位总生存19个月。

核心结论

  • 在WHO体能评分0-1的III期非小细胞肺癌患者中,同期铂类双药化疗与66 Gy/24次放疗后毒性出乎意料地高。

研究设计与样本

  • 回顾性观察研究,纳入2012至2017年41例III期非小细胞肺癌患者,年龄<70岁,WHO体能评分0-1,均接受同期铂类双药化疗与66 Gy/24次放疗,全部经PET扫描与脑MRI扫描分期。

主要发现

  • 中位随访4.7年,中位年龄57岁,58%为男性,68%为IIIB期,中位总肿瘤体积104 cc(范围15-367 cc),中位淋巴结肿瘤体积59 cc(范围10-341 cc)。
  • 5例患者死亡:4例死于食管穿孔或瘘,1例死于肺出血。
  • ≥3级食管毒性发生于16例患者,晚期≥3级食管毒性发生于5例患者(12%)。
  • 中位总生存为19个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Concurrent chemoradiation followed by immunotherapy is the standard of care for patients with stage III non-small cell lung cancer (NSCLC). Prior to the introduction of adjuvant immunotherapy, we treated patients with stage III NSCLC with concurrent platinum doublet chemotherapy and 66 Gy in 24 fractions. We determined the toxicity of this treatment. METHODS: A retrospective observational study was performed in a cohort of patients with stage III NSCLC, <70 years old, and WHO performance score 0-1. Patients were treated with concurrent platinum doublet chemotherapy and 66 Gy in 24 fractions. All patients were staged with a PET-scan and brain MRI-scan. Toxicity was scored using the common criteria for adverse events (CTCAE v4.03). RESULTS: Between 2012 and 2017, 41 patients were treated with mildly hypofractionated radiotherapy and platinum doublet chemotherapy. The median follow-up was 4.7 years. The median age was 57 and 58% of patients were male. The majority of patients had stage IIIB disease (68%). The median total Gross Tumor Volume (GTV) was 104 cc (range: 15-367 cc). The median lymph node GTV was 59 cc (10-341 cc). Five patients died: four due to an esophagus perforation or fistula, and one due to pulmonary bleeding. Grade ≥ 3 esophageal toxicity occurred in 16 patients. Five patients had late grade ≥ 3 esophageal toxicity (12%). The median overall survival was 19 months. CONCLUSION: Toxicity was unexpectedly high in patients with stage III NSCLC (WHO 0-1) after concurrent platinum doublet chemotherapy and 66 Gy in 24 fractions.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. van der Voort van Zyp N, Hashimzadah M, Kouwenhoven E, et al. Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy. Clin Transl Radiat Oncol. 2022. PMID: 35847053. doi:10.1016/j.ctro.2022.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。